Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery

In this 2-arm, non-randomized, phase II trial, the investigators will evaluate the efficacy and safety of comprehensive multimodal prehabilitation (CMMP) alone or in combination with planned neoadjuvant (NAT) in pre-frail/frail patients with probable/proven pancreaticobiliary, ovarian, kidney, or bladder cancer prior to elective major cancer surgery (EMCS).

Trial Details

NCT ID
NCT07050771
Phase
PHASE2
Sponsor
The Methodist Hospital Research Institute
Status
RECRUITING
Cancer Type
Bladder Cancer
Interventions
  • Comprehensive multimodal prehabilitation (CMMP)
Locations (sample)
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Patients are eligible for entry into the study (First Registration) only if ALL of the following criteria apply. No exceptions or waivers will be g…
  • Signed informed consent form.
  • Age ≥18 years at time of signing informed consent form.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 per the treating cancer surgeon (Arm 1, Neoadjuvant therapy) or per both the tr…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Bladder Cancer Trials on Trialify →